dc.date.accessioned | 2022-03-14T18:01:54Z | |
dc.date.available | 2022-03-14T18:01:54Z | |
dc.date.created | 2022-01-28T00:06:43Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Nunes-Xavier, Caroline Elisabeth Kildal, Wanja Kleppe, Andreas Danielsen, Håvard Emil Greger Wæhre, Håkon Llarena, Roberto Mælandsmo, Gunhild Mari Fodstad, Øystein Pulido, Rafael López, José I. . Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. The Prostate. 2021 | |
dc.identifier.uri | http://hdl.handle.net/10852/92455 | |
dc.description.abstract | Background
Novel immune checkpoint-based immunotherapies may benefit specific groups of prostate cancer patients who are resistant to other treatments.
Methods
We analyzed by immunohistochemistry the expression of B7-H3, PD-L1/B7-H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway.
Results
B7-H3 expression correlated positively with AR expression and was associated with biochemical recurrence in the Spanish cohort, but PD-L1 expression correlated with neither of them. Findings for B7-H3 were validated in the Norwegian cohort, where B7-H3 expression correlated positively with Gleason grade, surgical margins, seminal vesicle invasion, and CAPRA-S risk group, and was associated with clinical recurrence. High B7-H3 expression in the Norwegian cohort was also consistent with positive AR expression.
Conclusion
These results suggest distinct clinical relevance of the two immune checkpoint proteins PD-L1 and B7-H3 in prostate cancer. Our findings highlight B7-H3 as an actionable novel immune checkpoint protein in prostate cancer. | |
dc.language | EN | |
dc.publisher | Alan R. Liss Inc. | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.title | Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer | |
dc.type | Journal article | |
dc.creator.author | Nunes-Xavier, Caroline Elisabeth | |
dc.creator.author | Kildal, Wanja | |
dc.creator.author | Kleppe, Andreas | |
dc.creator.author | Danielsen, Håvard Emil Greger | |
dc.creator.author | Wæhre, Håkon | |
dc.creator.author | Llarena, Roberto | |
dc.creator.author | Mælandsmo, Gunhild Mari | |
dc.creator.author | Fodstad, Øystein | |
dc.creator.author | Pulido, Rafael | |
dc.creator.author | López, José I. | |
cristin.unitcode | 185,15,5,47 | |
cristin.unitname | Digital signalbehandling og bildeanalyse | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1991902 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The Prostate&rft.volume=&rft.spage=&rft.date=2021 | |
dc.identifier.jtitle | The Prostate | |
dc.identifier.volume | 81 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 838 | |
dc.identifier.endpage | 848 | |
dc.identifier.doi | https://doi.org/10.1002/pros.24180 | |
dc.identifier.urn | URN:NBN:no-95033 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0270-4137 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/92455/1/Immune%2Bcheckpoint%2BB7-H3%2Bprotein%2Bexpression%2Bis%2Bassociated%2Bwith%2Bpoor%2Boutcome%2Band%2Bandrogen%2Breceptor%2Bstatus%2Bin%2Bprostate%2Bcancer.pdf | |
dc.type.version | PublishedVersion | |